About Us

Contact us
Community Advisory Board
Readers Rep
Careers
Events
Historical Archives
Recent Quotes
My Watchlist
Indicators
Local Stocks
San Diego Stocks
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by AstraZeneca

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
News headline image
Camizestrant Combination Delayed Time to First Progression by 55% and to Second Progression by 37% in Patients With Advanced HR-positive Breast Cancer With an Emergent ESR1 Tumor Mutation in SERENA-6 Trial
From AstraZeneca
Via Business Wire
Tickers AZN
News headline image
IMFINZI® (durvalumab) plus IMJUDO® (tremelimumab-actl) combined with lenvatinib and TACE reduced the risk of disease progression or death by 30% in embolization-eligible unresectable liver cancer in EMERALD-3 Phase III trial
From AstraZeneca
Via Business Wire
Tickers AZN
News headline image
IMFINZI® (durvalumab) approved in the US in first and only immunotherapy combination for patients with BCG-naïve, high-risk non-muscle-invasive bladder cancer
From AstraZeneca
Via Business Wire
Tickers AZN
News headline image
DATROWAY® (datopotamab deruxtecan-dlnk) approved in the US as first TROP2-directed antibody drug conjugate for 1st-line treatment of patients with metastatic triple-negative breast cancer who are not PD-1/PD-L1 inhibitor candidates
From AstraZeneca
Via Business Wire
Tickers AZN
News headline image
AstraZeneca to showcase Phase III data in liver, breast and bladder cancers and potential first-in-class rare disease therapy at ASCO 2026
From AstraZeneca
Via Business Wire
Tickers AZN
News headline image
BAXFENDY approved in the US as the first and only aldosterone synthase inhibitor treatment for adults with hypertension
From AstraZeneca
Via Business Wire
Tickers AZN
News headline image
ENHERTU® (fam-trastuzumab deruxtecan-nxki) approved in the US for two new indications for patients with HER2-positive early breast cancer
From AstraZeneca
Via Business Wire
Tickers AZN
News headline image
Perioperative IMFINZI® (durvalumab) plus neoadjuvant EV showed statistically significant and clinically meaningful improvements in event-free survival and overall survival in muscle-invasive bladder cancer in the Phase III VOLGA trial
From AstraZeneca
Via Business Wire
Tickers AZN
News headline image
TRUQAP® (capivasertib) recommended by FDA Advisory Committee for PTEN-deficient metastatic hormone-sensitive prostate cancer
From AstraZeneca
Via Business Wire
Tickers AZN
News headline image
AstraZeneca results: Q1 2026
From AstraZeneca
Via Business Wire
Tickers AZN
News headline image
BREZTRI approved in the US for asthma as first and only triple therapy for patients 12 years of age and older
From AstraZeneca
Via Business Wire
Tickers AZN
News headline image
SAPHNELO approved in the US for subcutaneous self-administration as a new autoinjector for the treatment of systemic lupus erythematosus
From AstraZeneca
Via Business Wire
Tickers AZN
News headline image
Tozorakimab met primary endpoint in Phase III MIRANDA trial in patients with COPD
From AstraZeneca
Via Business Wire
Tickers AZN
News headline image
IMFINZI® (durvalumab) + IMJUDO® (tremelimumab-actl) improves PFS in early liver cancer
From AstraZeneca
Via Business Wire
Tickers AZN
News headline image
Tozorakimab met primary endpoint in both OBERON and TITANIA Phase III trials in patients with COPD
From AstraZeneca
Via Business Wire
Tickers AZN
News headline image
AstraZeneca and Joshua Jackson partner to encourage fans to Get Body Checked Against Cancer
From AstraZeneca
Via Business Wire
Tickers AZN
News headline image
ENHERTU® (fam-trastuzumab deruxtecan-nxki) granted Priority Review in the US as post-neoadjuvant treatment for patients with HER2-positive early breast cancer
From AstraZeneca
Via Business Wire
Tickers AZN
News headline image
CALQUENCE® plus venetoclax approved in the US as first all-oral, fixed-duration combination for patients with chronic lymphocytic leukemia in the 1st-line setting
From AstraZeneca
Via Business Wire
Tickers AZN
News headline image
Positive and clinically meaningful results from the Phase III KALOS and LOGOS trials for BREZTRI in patients with uncontrolled asthma published in The Lancet Respiratory Medicine
From AstraZeneca
Via Business Wire
Tickers AZN
News headline image
AstraZeneca awards $3.4 million for programs to improve access to healthcare for patients across the US
From AstraZeneca
Via Business Wire
Tickers AZN
News headline image
AstraZeneca results: FY and Q4 2025
From AstraZeneca
Via Business Wire
Tickers AZN
News headline image
DATROWAY® (datopotamab deruxtecan-dlnk) granted Priority Review in the US as 1st-line treatment for patients with metastatic triple-negative breast cancer who are not candidates for immunotherapy
From AstraZeneca
Via Business Wire
Tickers AZN
News headline image
AstraZeneca begins trading on the New York Stock Exchange
From AstraZeneca
Via Business Wire
Tickers AZN
News headline image
Rick R. Suarez appointed US President and Head of US BioPharmaceuticals Business Unit
From AstraZeneca
Via Business Wire
Tickers AZN
News headline image
ENHERTU® (fam-trastuzumab deruxtecan-nxki) granted Breakthrough Therapy Designation in the US as post-neoadjuvant therapy for patients with HER2-positive early breast cancer
From AstraZeneca
Via Business Wire
Tickers AZN
News headline image
ENHERTU® (fam-trastuzumab deruxtecan-nxki) plus pertuzumab approved in the US as first new treatment in a decade for the 1st-line treatment of patients with HER2-positive metastatic breast cancer
From AstraZeneca
Via Business Wire
Tickers AZN
News headline image
AstraZeneca advances hematology and cell therapy ambition with largest-ever presence at ASH
From AstraZeneca
Via Business Wire
Tickers AZN
News headline image
Baxdrostat New Drug Application accepted under FDA Priority Review in the US for patients with hard-to-control hypertension
From AstraZeneca
Via Business Wire
Tickers AZN
News headline image
IMFINZI® approved in the US as first and only perioperative immunotherapy for patients with early gastric and gastroesophageal cancers
From AstraZeneca
Via Business Wire
Tickers AZN
News headline image
AstraZeneca plans $2 billion manufacturing investment in Maryland, supporting 2,600 jobs and catalyzing economic growth
From AstraZeneca
Via Business Wire
Tickers AZN
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.